Symptom cluster of fatigue, sleep disturbance and depression and its impact on quality of life among Chinese breast cancer patients undergoing adjuvant chemotherapy: A cross-sectional study
Refereed conference paper presented and published in conference proceedings


Times Cited
Web of Science1WOS source URL (as at 01/12/2021) Click here for the latest count
Altmetrics Information
.

Other information
AbstractBackground:
Breast cancer (BC) itself and curative treatments can cause various concurrent distressing symptoms. These symptoms may “cluster” together and create a synergistic impact compared to a single symptom on patients' quality of life (QoL). Among various symptom clusters identified in BC population, the cluster of fatigue, sleep disturbance and depression (F-S-D) is frequently reported during active adjuvant chemotherapy. A cross-sectional study was conducted to evaluate this symptom cluster in Chinese BC patients and explore its impact on QoL.

Methods:
Female adults currently receiving adjuvant chemotherapy for BC in two tertiary public hospitals in Xi’an, China were recruited in this study. Four validated measurements were used: Chinese version of Brief Fatigue Inventory, Pittsburgh Sleep Quality Index, Patient Health Questionnaire-Depression, and Functional Assessment of Cancer Therapy-Breast. Patient-rated outcomes were measured on day-8 of recently received chemotherapy via face-to-face or telephone call. Descriptive statistics, Spearman correlation and One way ANOVA were used in data analysis.

Results:
A total of 372 consented subjects with a mean age of 50.1±9.2 years completed the survey. Most of them were married, diagnosed with I-II stage BC, and undergone mastectomy. 99.2% of subjects experienced with fatigue, 87.4% were poor sleepers, while 93.3% had depressive symptom. The proportions of subjects who experiencing 0, 1, 2 and 3 symptoms were 0.8%, 3.0%, 11.8% and 84.4%, respectively. Spearman correlation analysis showed that fatigue, sleep disturbance and depression were significantly correlated with each other (RFS=.45, RFD=.57, RSD=.50, all P<0.001), and each of the single symptoms was negatively related to QoL (RFQ=-.57, RSQ=-.35, RDQ=-.60, all P<0.001). When using One way ANOVA to explore the influence of symptom cluster on QoL, we found that there was a significant (F=34.76, P<0.001) decreasing trend in QoL across BC patients experiencing an increased number of symptoms (F-S-D).

Conclusions:
The symptom cluster of F-S-D exists in most BC patients and it adversely affects their QoL.
Acceptance Date18/07/2019
All Author(s) ListXiaole HE, Winnie K.W. SO, K.C. CHOI, Lulu LI, Wenqian ZHAO, Mengyue ZHANG
Name of Conference44th Congress of the European-Society-for-Medical-Oncology (ESMO)
Start Date of Conference27/09/2019
End Date of Conference01/10/2019
Place of ConferenceBarcelona, Spain
Country/Region of ConferenceSpain
Proceedings TitleAnnals of Oncology
Year2019
Month10
Volume Number30
Issue NumberSupplement 5
Pages840 - 840
ISSN0923-7534
LanguagesEnglish-United Kingdom

Last updated on 2021-01-12 at 23:47